SeaStar Medical is a medical technology company that is redefining how extracorporeal therapies can address the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel selective cytopheretic device (SCD) is cell-directed extracorporeal therapy designed to provide life-saving solutions to critically ill patients. The SCD easily incorporates into current installed continuous renal replacement therapy (CRRT) systems. The SCD targets the key immune cells that drive systemic inflammation responsible for causing direct tissue damage and organ failure. In 2024, the SCD was granted a humanitarian device exemption by FDA for pediatric AKI due to sepsis (brand name QUELimmuneTM) and has received several Breakthrough Device Designations including in adult AKI, cardiorenal syndrome, and most recently in chronic dialysis.

www.seastarmedical.com